1.Study Progresses in Triterpenes of Poria cocos and Its Pharmacology
Zhaojin ZHONG ; Jun LIU ;
Chinese Traditional Patent Medicine 1992;0(01):-
Objective:To Review the study progresses in triterpenes of poria cocos of effective ingredients its pharmacology and biological activity.Methods:The study progresses were reviewed on the basis of summinmg up and analying the collected articles.Results:Poria cocos has types of triterpenes including more than thirty kinds of the mical components. Different tritepenes showed different effects of anti tumour, anti inflammation and immunity.Conclusion:The resources of Poria cocos are rich in China. It is worthy of exploiting and utilizing Poria cocos in conjunction with the achievement in modern chemistry and pharmacology studies.
3.A novel rapid fluorescence focus inhibition test for the detection of rabies virus antibody
Hongru LIANG ; Xiaohui LIU ; Jing CHEN ; Zhaojin SUN ; Xiaofeng GUO
Chinese Journal of Zoonoses 2009;(7):619-622
The objective of the present study was to establish a novel rapid fluorescence focus inhibition test (RFFIT GFP)for the detection of rabies virus antibody, in which a chimeric rabies virus expressing green fluorescent protein (HEP GFP) was used as the basic virus strain in RFFIT GFP assay, and a few serum samples from human, dog and cat were detected by this new method .The optimal serum dilution, virus dosage and infection time were determined in 24 serum samples from human, dog and cat by using RFFIT GFP, RFFIT and ELISA assays. The result showed that these 3 methods gave a good consistency. But RFFIT GFP was found to be more convenient and economic for the detection of rabies virus antibody.
4. Cause and control of non-sampling error in China National Human Biomonitoring Program
Yingli QU ; Feng ZHAO ; Ling LIU ; Shixun SONG ; Yingchun LIU ; Jiayi CAI ; Zhaojin CAO ; Xiaoming SHI
Chinese Journal of Preventive Medicine 2019;53(1):107-111
The size of the non-sampling error is directly related to the accuracy and reliability of the sampling survey result. This paper studied the non-sampling errors generated during the sampling process of the China National Human Biomonitoring Program(CNBP), mainly including the sampling frame error, non-response error and measurement error. The program reduced the influence of the non-sampling error on the quality of the survey effectively by scientifically designing the sampling scheme and questionnaire, strengthening investigator trainings and standardizing the data review, which could be used to provide reference for the control of non-sampling errors in public health monitoring projects in China.
5.Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
Yu Jun WONG ; Chen ZHAOJIN ; Guilia TOSETTI ; Elisabetta DEGASPERI ; Sanchit SHARMA ; Samagra AGARWAL ; Liu CHUAN ; Chan Yiong HUAK ; Li JIA ; Qi XIAOLONG ; Anoop SARAYA ; Massimo PRIMIGNANI
Clinical and Molecular Hepatology 2023;29(1):135-145
Background/Aims:
The utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease (cACLD) patient needs validation. We aim to validate the performance of CSPH criteria to predict the risk of decompensation in an international real-world cohort of cACLD patients.
Methods:
cACLD patients were stratified into three categories (CSPH excluded, grey zone, and CSPH). The risks of decompensation across different CSPH categories were estimated using competing risk regression for clustered data, with death and hepatocellular carcinoma as competing events. The performance of “treating definite CSPH” strategy to prevent decompensation using non-selective beta-blocker (NSBB) was compared against other strategies in decision curve analysis.
Results:
One thousand one hundred fifty-nine cACLD patients (36.8% had CSPH) were included; 7.2% experienced decompensation over a median follow-up of 40 months. Non-invasive assessment of CSPH predicts a 5-fold higher risk of liver decompensation in cACLD patients (subdistribution hazard ratio, 5.5; 95% confidence interval, 4.0–7.4). “Probable CSPH” is suboptimal to predict decompensation risk in cACLD patients. CSPH exclusion criteria reliably exclude cACLD patients at risk of decompensation, regardless of etiology. Among the grey zone, the decompensation risk was negligible among viral-related cACLD, but was substantially higher among the non-viral cACLD group. Decision curve analysis showed that “treating definite CSPH” strategy is superior to “treating all varices” or “treating probable CSPH” strategy to prevent decompensation using NSBB.
Conclusions
Non-invasive assessment of CSPH may stratify decompensation risk and the need for NSBB in cACLD patients.
6.Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Chen FU ; Lifeng YU ; Yuxi MIAO ; Xinli LIU ; Zhaojin YU ; Minjie WEI
Acta Pharmaceutica Sinica B 2023;13(2):498-516
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in the last two years, the pharmaceutical companies have been developing PDCs as targeted therapeutic candidates for cancer, coronavirus disease 2019 (COVID-19), metabolic diseases, and so on. The therapeutic benefits of PDCs are significant, but poor stability, low bioactivity, long research and development time, and slow clinical development process as therapeutic agents of PDC, how can we design PDCs more effectively and what is the future direction of PDCs? This review summarises the components and functions of PDCs for therapeutic, from drug target screening and PDC design improvement strategies to clinical applications to improve the permeability, targeting, and stability of the various components of PDCs. This holds great promise for the future of PDCs, such as bicyclic peptide‒toxin coupling or supramolecular nanostructures for peptide-conjugated drugs. The mode of drug delivery is determined according to the PDC design and current clinical trials are summarised. The way is shown for future PDC development.
7. Current status of body mass index and related influencing factors in the elderly aged 65 years and older in 8 longevity areas in China
Yingjian ZHANG ; Yuebin LYU ; Jinhui ZHOU ; Feng ZHAO ; Yingli QU ; Ling LIU ; Yingchun LIU ; Jiaonan WANG ; Zhaojin CAO ; Shiman RUAN ; Xiaoming SHI
Chinese Journal of Epidemiology 2020;41(1):25-30
Objective:
To understand the current status of BMI of the elderly and related factors in longevity areas in China, and provide scientific evidence for the control of BMI level in elderly population.
Methods:
Data used in this study were obtained from Healthy Aging and Biomarkers Cohort Study, a sub-cohort of the Chinese Longitudinal Healthy Longevity Survey. A total of 2 825 elderly in 8 longevity areas in China were surveyed and measured in 2017. The BMI levels of 2 217 elderly aged 65 years and older were calculated and in follow up. The ordered classification logistic regression model was used to analyze the influencd factors for the BMI in the elderly.
Results:
The BMI of the elderly in 8 longevity areas in China was (22.36±3.87) kg/m2, and it was (22.76±3.58) kg/m2 for males and (21.75±3.98) kg/m2 for females. The BMI levels were normal in 1 165 elderly persons. The prevalence of underweight, overweight and obesity were 15.8
8. Association of arsenic with unexplained recurrent spontaneous abortion: a case-control study
Yuanyuan LI ; Suwen CHEN ; Feng ZHAO ; Huimin ZHANG ; Wenli ZHANG ; Yingli QU ; Yingchun LIU ; Heng GU ; Jiayi CAI ; Zhaojin CAO ; Xiaoming SHI
Chinese Journal of Preventive Medicine 2019;53(5):470-474
Objective:
To explore the association of arsenic with unexplained recurrent spontaneous abortion (URSA).
Methods:
A case-control study was conducted to select URSA patients who were admitted to the Beijing Maternal and Child Health Care Hospital affiliated to Capital Medical University from April to October 2018 as a case group. Women who had a normal pregnancy in the Family Planning Department of the hospital but volunteered to have an abortion were selected as a control group. The case and control group were paired in a 1: 1 ratio. The inclusion criteria of the case group were patients with newly diagnosed recurrent spontaneous abortion who had clinically confirmed more than 2 spontaneous abortions and had 20 weeks prior to pregnancy, excluding patients with recurrent spontaneous abortion caused by abnormal blood coagulation (anti-phospholipid antibody positive), abnormal physiological anatomy (B-ultrasound), abnormal immune factors (anti-nuclear antibody positive, anti-cardiolipin antibody, etc.), genetic chromosomal abnormalities (karyotype analysis) and pathogenic microbial infection. The control group was matched according to the age of the case group (±3 years old) and the gestational age (±2 weeks) to exclude adverse pregnancy outcomes such as stillbirth, congenital malformation, premature delivery and low birth weight infants. A total of 192 subjects were included. Questionnaires were used to collect information of all subjects, and 12 ml of peripheral venous blood was collected to detect blood arsenic levels. Blood arsenic levels were divided into low concentration group (<1.00 μg/L), medium concentration group (1.00-1.50 μg/L) and high concentration group (>1.50 μg/L). The multivariate conditional logistic regression was performed to analyze the relationship between blood arsenic exposure and URSA and explore the influencing factors of blood Arsenic.
Results:
The geometric mean values of blood arsenic level in the cases group and control group were 1.68 (1.50-1.86) μg/L and 1.26 (1.17-1.37) μg/L, respectively. The blood arsenic level in the case group was significantly higher than that in the control group (
9. Influencing factors for depressive symptoms in the elderly aged 65 years and older in 8 longevity areas in China
Qi KANG ; Yuebin LYU ; Yuan WEI ; Wanying SHI ; Jun DUAN ; Jinhui ZHOU ; Jiaonan WANG ; Feng ZHAO ; Yingli QU ; Ling LIU ; Yingchun LIU ; Zhaojin CAO ; Qiong YU ; Xiaoming SHI
Chinese Journal of Epidemiology 2020;41(1):20-24
Objective:
To analyze influencing factors for depressive symptoms in the elderly aged 65 years and older in 8 longevity areas in China.
Methods:
We recruited 2 180 participants aged 65 years and older in 8 longevity areas from Healthy Aging and Biomarkers Cohort Study, a sub-cohort of the Chinese Longitudinal Healthy Longevity Survey in 2017. Multivariate logistic regression analysis was performed to evaluate the relationships of socio-demographic characteristics, behavioral lifestyle, chronic disease prevalence, functional status, family and social support with depressive symptoms in the elderly.
Results:
The detection rate of depression symptoms was 15.0
10. Influence of visual impairment on mortality in the elderly aged 65 years and older in 8 longevity areas in China
Miaochun CAI ; Feng ZHAO ; Dong SHEN ; Yuebin LYU ; Xiru ZHANG ; Jinhui ZHOU ; Yingli QU ; Ling LIU ; Yingchun LIU ; Jiaonan WANG ; Zhaojin CAO ; Xianbo WU ; Xiaoming SHI ; Chen MAO
Chinese Journal of Epidemiology 2020;41(1):31-35
Objective:
To understand the relationship between visual impairment and risk of all-cause mortality in the elderly aged 65 years and older in 8 longevity areas in China.
Methods:
The data of the elderly aged 65 years and older in the project in 2012 were obtained from Healthy Aging and Biomarkers Cohort Study, a sub-cohort of the Chinese Longitudinal Healthy Longevity Survey, including physical measurement and survival status, and a follow-up for survival outcomes were conducted in 2014 and 2017 respectively. Cox proportional hazard regression model was used to analyze the influence of visual impairment on mortality. Gender and age specific analysis was conducted.
Results:
A total of 1 736 elderly adults were included. A total of 943 deaths occurred during the 5-year follow-up period with a 5-year mortality rate of 54.3